MA33302B1 - 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale - Google Patents
2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormaleInfo
- Publication number
- MA33302B1 MA33302B1 MA34394A MA34394A MA33302B1 MA 33302 B1 MA33302 B1 MA 33302B1 MA 34394 A MA34394 A MA 34394A MA 34394 A MA34394 A MA 34394A MA 33302 B1 MA33302 B1 MA 33302B1
- Authority
- MA
- Morocco
- Prior art keywords
- excessive
- treatment
- cell proliferation
- abnormal cell
- diseases characterized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRÉSENTE INVENTION PORTE SUR DES COMPOSÉS DE FORMULE GÉNÉRALE (1), DANS LAQUELLE A, B, R1 À R5, RX M, N ET P SONT TELS QUE DÉFINIS DANS LA REVENDICATION 1, QUI SONT APPROPRIÉS POUR LE TRAITEMENT DE MALADIES CARACTÉRISÉES PAR UNE PROLIFÉRATION CELLULAIRE EXCESSIVE OU ANORMALE. L'INVENTION PORTE ÉGALEMENT SUR DES PRÉPARATIONS PHARMACEUTIQUES QUI CONTIENNENT DE TELS COMPOSÉS ET SUR LEUR UTILISATION EN TANT QUE MÉDICAMENTS.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09161496 | 2009-05-29 | ||
EP10161628 | 2010-04-30 | ||
PCT/EP2010/057408 WO2010136559A1 (fr) | 2009-05-29 | 2010-05-28 | 2, 4-diaminopyrimidines pour le traitement de maladies caractérisées par une prolifération cellulaire excessive ou anormale |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33302B1 true MA33302B1 (fr) | 2012-05-02 |
Family
ID=42289495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34394A MA33302B1 (fr) | 2009-05-29 | 2010-05-28 | 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale |
Country Status (22)
Country | Link |
---|---|
US (1) | US8410126B2 (fr) |
EP (1) | EP2435411B1 (fr) |
JP (1) | JP5756799B2 (fr) |
KR (1) | KR20120135010A (fr) |
CN (1) | CN102448943A (fr) |
AP (1) | AP2011005978A0 (fr) |
AR (1) | AR076620A1 (fr) |
AU (1) | AU2010251943A1 (fr) |
BR (1) | BRPI1014994A2 (fr) |
CA (1) | CA2763700A1 (fr) |
CL (1) | CL2011003022A1 (fr) |
CO (1) | CO6470899A2 (fr) |
EA (1) | EA201101674A1 (fr) |
EC (1) | ECSP11011558A (fr) |
IL (1) | IL216084A0 (fr) |
MA (1) | MA33302B1 (fr) |
MX (1) | MX2011012643A (fr) |
PE (1) | PE20120370A1 (fr) |
SG (1) | SG176599A1 (fr) |
TW (1) | TW201107308A (fr) |
UY (1) | UY32673A (fr) |
WO (1) | WO2010136559A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090019011A (ko) * | 2006-06-15 | 2009-02-24 | 베링거 인겔하임 인터내셔날 게엠베하 | 단백질 키나아제 c-알파의 억제제로서의 2-아닐리노-4-(헤테로사이클릭)아미노-피리미딘 |
LT2300013T (lt) | 2008-05-21 | 2017-12-27 | Ariad Pharmaceuticals, Inc. | Fosforo dariniai kaip kinazių inhibitoriai |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
CN103534240B (zh) | 2011-02-17 | 2015-12-09 | 癌症疗法Crc私人有限公司 | 选择性fak抑制剂 |
EP2675793B1 (fr) | 2011-02-17 | 2018-08-08 | Cancer Therapeutics Crc Pty Limited | Inhibiteurs de fak |
CN103501612B (zh) | 2011-05-04 | 2017-03-29 | 阿里亚德医药股份有限公司 | 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物 |
US20150166591A1 (en) | 2012-05-05 | 2015-06-18 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
ES2940911T3 (es) * | 2016-06-27 | 2023-05-12 | Rigel Pharmaceuticals Inc | Compuestos de 2,4-diamino-pirimidina y su uso como inhibidores de IRAK4 |
KR20190114910A (ko) * | 2018-03-30 | 2019-10-10 | 한미약품 주식회사 | 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체 |
KR20240019071A (ko) * | 2021-04-02 | 2024-02-14 | 브릿지바이오테라퓨틱스(주) | N2-페닐피리미딘-2,4-디아민 화합물, 및 그 제조 방법 및 사용 방법 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA02011376A (es) * | 2000-05-22 | 2004-02-26 | Leo Pharma As | Benzofenonas como inhibidores de il-1beta y tnf-alfa. |
WO2003030909A1 (fr) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer |
ATE407678T1 (de) * | 2001-10-17 | 2008-09-15 | Boehringer Ingelheim Pharma | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
CA2490888C (fr) * | 2002-06-28 | 2011-05-24 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de diaminopyrimidinecarboxamide |
US7109337B2 (en) * | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
GEP20084357B (en) * | 2002-12-20 | 2008-04-29 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
AP2241A (en) * | 2004-05-14 | 2011-06-01 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth. |
US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
PE20120006A1 (es) | 2006-05-15 | 2012-02-02 | Boehringer Ingelheim Int | Compuestos derivados de pirimidina como inhibidores de la quinasa aurora |
DK2089369T3 (da) * | 2006-10-19 | 2011-05-09 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme |
US8138339B2 (en) * | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
VN29259A1 (en) * | 2008-04-16 | 2012-04-25 | Portola Pharm Inc | 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors |
-
2010
- 2010-05-21 US US12/784,813 patent/US8410126B2/en active Active
- 2010-05-28 AU AU2010251943A patent/AU2010251943A1/en not_active Abandoned
- 2010-05-28 AP AP2011005978A patent/AP2011005978A0/xx unknown
- 2010-05-28 EP EP10724385.9A patent/EP2435411B1/fr active Active
- 2010-05-28 JP JP2012512388A patent/JP5756799B2/ja active Active
- 2010-05-28 MA MA34394A patent/MA33302B1/fr unknown
- 2010-05-28 TW TW099117275A patent/TW201107308A/zh unknown
- 2010-05-28 AR ARP100101883A patent/AR076620A1/es unknown
- 2010-05-28 BR BRPI1014994A patent/BRPI1014994A2/pt not_active Application Discontinuation
- 2010-05-28 MX MX2011012643A patent/MX2011012643A/es not_active Application Discontinuation
- 2010-05-28 KR KR1020117031173A patent/KR20120135010A/ko not_active Application Discontinuation
- 2010-05-28 PE PE2011002012A patent/PE20120370A1/es not_active Application Discontinuation
- 2010-05-28 WO PCT/EP2010/057408 patent/WO2010136559A1/fr active Application Filing
- 2010-05-28 UY UY0001032673A patent/UY32673A/es not_active Application Discontinuation
- 2010-05-28 CN CN2010800234907A patent/CN102448943A/zh active Pending
- 2010-05-28 SG SG2011086790A patent/SG176599A1/en unknown
- 2010-05-28 CA CA2763700A patent/CA2763700A1/fr not_active Abandoned
- 2010-05-28 EA EA201101674A patent/EA201101674A1/ru unknown
-
2011
- 2011-11-01 IL IL216084A patent/IL216084A0/en unknown
- 2011-11-29 CL CL2011003022A patent/CL2011003022A1/es unknown
- 2011-12-15 CO CO11173252A patent/CO6470899A2/es not_active Application Discontinuation
- 2011-12-27 EC EC2011011558A patent/ECSP11011558A/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20120370A1 (es) | 2012-05-09 |
SG176599A1 (en) | 2012-01-30 |
AP2011005978A0 (en) | 2011-12-31 |
KR20120135010A (ko) | 2012-12-12 |
CA2763700A1 (fr) | 2010-12-02 |
CN102448943A (zh) | 2012-05-09 |
AU2010251943A1 (en) | 2011-12-01 |
UY32673A (es) | 2010-12-31 |
WO2010136559A1 (fr) | 2010-12-02 |
AR076620A1 (es) | 2011-06-22 |
US20110130401A1 (en) | 2011-06-02 |
EA201101674A1 (ru) | 2012-06-29 |
JP5756799B2 (ja) | 2015-07-29 |
EP2435411B1 (fr) | 2014-10-29 |
US8410126B2 (en) | 2013-04-02 |
BRPI1014994A2 (pt) | 2016-05-03 |
IL216084A0 (en) | 2012-01-31 |
JP2012528121A (ja) | 2012-11-12 |
CO6470899A2 (es) | 2012-06-29 |
CL2011003022A1 (es) | 2012-07-13 |
MX2011012643A (es) | 2011-12-14 |
EP2435411A1 (fr) | 2012-04-04 |
ECSP11011558A (es) | 2012-01-31 |
TW201107308A (en) | 2011-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33302B1 (fr) | 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale | |
TN2009000551A1 (fr) | Nouveaux composes chimiques | |
MA50240A (fr) | Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation | |
MA34308B1 (fr) | Triazolopyridines substituées | |
MA32506B1 (fr) | Nouveaux composes | |
MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
MA41562B1 (fr) | Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires | |
MA33606B1 (fr) | Dérivés de pyrimidine en tant qu'inhibiteurs de protéine tyrosine kinase 2 | |
MA34727B1 (fr) | Imidazolylimidazoles condensés utilisés comme composés antiviraux | |
MA34474B1 (fr) | Agonistes de gpr40 | |
MA31260B1 (fr) | 3-imidazolyl-indoles pour le traitement de maladies proliferatives | |
MA31764B1 (fr) | Composés et compositions en tant que modulateurs de l'activité de gpr119 | |
TW200612926A (en) | Compounds and compositions as ppar modulators | |
MA33419B1 (fr) | Composés et compositions pour le traitement de maladies parasitaires | |
MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
MA30324B1 (fr) | Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine. | |
MA29377B1 (fr) | Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif | |
TN2015000547A1 (fr) | Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1 | |
MA30514B1 (fr) | Nouveaux composes. | |
MA37990B1 (fr) | Benzamides | |
MA33218B1 (fr) | Applications therapeutiques de derives de quinazolinedione | |
MA31857B1 (fr) | N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci | |
MA33242B1 (fr) | Composes pour le traitement de troubles metaboliques | |
MA37691B1 (fr) | 5-amino[1,4]thiazines comme inhibiteurs de bace1 | |
MA29723B1 (fr) | Composes |